公开(公告)号：US10588910B2

公开(公告)日：2020-03-17

申请号：US16315536

申请日：2017-07-05

Applicant: VASTHERA CO. LTD.

Inventor： Sang Won Kang ,  Ki Hwan Kwon

IPC: A61K31/548 ,  A61P9/12 ,  A61K31/407 ,  C07D513/08 ,  A61K31/549

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating pulmonary arterial hypertension, which comprises an epidithiodioxopiperazine (ETP) compound or a derivative thereof, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US10450327B2

公开(公告)日：2019-10-22

申请号：US16024454

申请日：2018-06-29

Applicant: VASTHERA Co. Ltd.

Inventor： Sang Won Kang ,  Dong Hoon Kang ,  Doo Jae Lee

IPC: C07D513/08 ,  C12Q1/26 ,  A61K31/00 ,  A61K31/548

Abstract: The present invention relates to an epidithiodioxopiperazine derivative represented by the following Chemical Formula 1 or its reduced derivative; a method for preparing a compound represented by Chemical Formula 1 having improved intracellular permeability and mimicking the activity of 2-Cys-Prx in its reduced form in the cells; a pharmaceutical composition for preventing or treating vascular diseases comprising an epidithiodioxopiperazine compound or its derivatives or pharmaceutically acceptable salts thereof as an active ingredient; a drug delivery device for local administration including the pharmaceutical composition; and a pharmaceutical composition for inhibiting melanoma metastasis comprising the epidithiodioxopiperazine compound or its derivatives or pharmaceutically acceptable salts thereof as an active ingredient.